These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 15727077)
1. Oral fluoropyrimidines in colorectal cancer: a door open to the future? Delaunoit T; Neczyporenko F; Hendlisz A; Eisendrath P; Bleiberg H Acta Gastroenterol Belg; 2004; 67(4):331-3. PubMed ID: 15727077 [TBL] [Abstract][Full Text] [Related]
2. Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results. Benson AB Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):28-34. PubMed ID: 9830622 [TBL] [Abstract][Full Text] [Related]
3. New options for outpatient chemotherapy--the role of oral fluoropyrimidines. Cunningham D; Coleman R Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541 [TBL] [Abstract][Full Text] [Related]
4. Oral therapy for colorectal cancer: how to choose. Damjanov N; Meropol NJ Oncology (Williston Park); 2000 Jun; 14(6):799-807; discussion 807-8, 813-4,. PubMed ID: 10887632 [TBL] [Abstract][Full Text] [Related]
5. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer. Iqbal S; Lenz HJ Expert Rev Anticancer Ther; 2004 Dec; 4(6):947-55. PubMed ID: 15606325 [TBL] [Abstract][Full Text] [Related]
6. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667 [TBL] [Abstract][Full Text] [Related]
7. Practical considerations in the use of oral fluoropyrimidines. Hoff PM Semin Oncol; 2003 Jun; 30(3 Suppl 6):88-92. PubMed ID: 12802799 [TBL] [Abstract][Full Text] [Related]
8. Role of oral chemotherapy in colorectal cancer. Donehower RC Oncology (Williston Park); 2000 Nov; 14(11A):243-5. PubMed ID: 11195416 [TBL] [Abstract][Full Text] [Related]
9. Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer. Cunningham D; James RD Eur J Cancer; 2001 May; 37(7):826-34. PubMed ID: 11313169 [TBL] [Abstract][Full Text] [Related]
10. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. Saif MW Clin Colorectal Cancer; 2005 Jul; 5(2):89-100. PubMed ID: 16098249 [TBL] [Abstract][Full Text] [Related]
11. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Twelves C; Gollins S; Grieve R; Samuel L Ann Oncol; 2006 Feb; 17(2):239-45. PubMed ID: 16344278 [TBL] [Abstract][Full Text] [Related]
12. Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer? Douillard JY; Bennouna J; Senellart H Clin Colorectal Cancer; 2008 May; 7(3):206-11. PubMed ID: 18621641 [TBL] [Abstract][Full Text] [Related]
13. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. Deboever G; Hiltrop N; Cool M; Lambrecht G Clin Colorectal Cancer; 2013 Mar; 12(1):8-14. PubMed ID: 23102544 [TBL] [Abstract][Full Text] [Related]
18. First-line capecitabine is as effective as 5-fluorouracil/leucovorin in treating advanced colorectal cancer. Gambill BD Clin Colorectal Cancer; 2001 May; 1(1):18-9. PubMed ID: 12445375 [No Abstract] [Full Text] [Related]
19. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Con: Pumpin' FU (or, avoiding that oral fixation). Hochster HS Clin Adv Hematol Oncol; 2005 May; 3(5):405-6. PubMed ID: 16167014 [No Abstract] [Full Text] [Related]
20. Oral fluoropyrimidines: a closer look at their toxicities. Macdonald JS Am J Clin Oncol; 1999 Oct; 22(5):475-80. PubMed ID: 10521062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]